instrument used, etc.) may lead to spurious, study-specific OTUs (for example, the GC bias of the Illumina platform can lead to sequences that contain more GC than another platform which can result in OTUs specific to the platform even if the biological origin of the amplicon is the same). As a result, a meta-analysis that uses a de novo strategy must redo OTU picking after combining the sequence data from the studies.
